BOSTON — CellCentric has raised $220 million in an oversubscribed Series D financing to advance pivotal clinical trials of inobrodib, its investigational oral treatment for multiple myeloma.
The clinical-stage biotechnology company, which is based in Cambridge, England, and Boston, is developing inobrodib as a first-in-class oral p300/CBP inhibitor.
The financing was led by Venrock Healthcare Capital Partners, with participation from Fidelity Management & Research Company, Sofinnova Partners and HBM Healthcare. Existing investors RA Capital Management, Forbion, Pfizer, Avego BioScience Capital and American Cancer Society BrightEdge also participated.
CellCentric said the proceeds will support registration-enabling trials, including continued enrollment in its recently initiated Phase 2 DOMMINO-1 study in the U.K. and U.S. and the launch of its global Phase 3 DOMMINO-2 trial in the second half of 2026. The funding will also support expansion of inobrodib into additional combination and maintenance treatment settings.
“We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need,” said Will West, Ph.D., CEO of CellCentric. “Inobrodib is a new modality and a potential fresh option for patients that is orally administered. In combination with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated relapsed or refractory multiple myeloma patients. Fueled by this funding, we are well positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.”
The company said Phase 2 dose-optimization data presented in December 2025 at the American Society of Hematology meeting showed that 20 mg of inobrodib in combination with standard doses of pomalidomide and dexamethasone, known as InoPd, produced at least a twofold increase in response rates compared with historical alternative therapies in heavily pretreated patients with relapsed or refractory multiple myeloma. Patients in the study had received a median of five prior lines of therapy.
“What stands out with inobrodib is the consistency of clinical activity alongside a manageable safety profile in a heavily pretreated population,” said Ken Greenberg, M.D., partner at Venrock. “An oral drug with a novel, additive approach could play an important role in later-line therapy, as well as across the treatment landscape in multiple myeloma. We are excited to support its advancement into pivotal studies.”
